<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956680</url>
  </required_header>
  <id_info>
    <org_study_id>CA046-006</org_study_id>
    <secondary_id>2018-003610-41</secondary_id>
    <nct_id>NCT03956680</nct_id>
  </id_info>
  <brief_title>An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers</brief_title>
  <official_title>A Phase I Study of BMS-986301 Monotherapy and Combination Therapy With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to characterize the safety, tolerability, dose limiting&#xD;
      toxicities, best route of administration, maximum tolerated dose, maximum administered dose,&#xD;
      or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in&#xD;
      participants with cancers that have failed to respond to T cell checkpoint inhibiting&#xD;
      antibodies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLTs)</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From Baseline until study exit (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>From Baseline until study exit (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>From Baseline until study exit (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>From Baseline until study exit (up to approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>From Baseline until disease progression (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>From Baseline until disease progression (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>From Baseline until disease progression (approximately 2 years)</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Advanced Solid Cancers</condition>
  <arm_group>
    <arm_group_label>Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986301</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)</arm_group_label>
    <arm_group_label>Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study</arm_group_label>
    <arm_group_label>Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study</arm_group_label>
    <arm_group_label>Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)</arm_group_label>
    <arm_group_label>Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study</arm_group_label>
    <arm_group_label>Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study</arm_group_label>
    <arm_group_label>Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1A Group 1: BMS-986301 Monotherapy Intramuscular (IM)</arm_group_label>
    <arm_group_label>Part 1A Group 2: BMS-986301 Monotherapy Intratumoral (I-TUMOR) Sub-study</arm_group_label>
    <arm_group_label>Part 1A Group 3: BMS-986301 Monotherapy Intravenous (IV) Sub-study</arm_group_label>
    <arm_group_label>Part 1B Group 4: Systemic BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 1B Group 5: I-TUMOR BMS-986301 + Nivolumab + Ipilimumab</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced unresectable/metastatic malignancy&#xD;
             of the squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung&#xD;
             cancer (NSCLC), melanoma, renal cell carcinoma (RCC), triple negative breast cancer&#xD;
             (TNBC), and urothelial carcinoma (UCC), that are refractory to or intolerant of&#xD;
             existing therapy(ies) known to provide clinical benefit for the condition of the&#xD;
             participant&#xD;
&#xD;
          -  Must have experienced radiographically documented progressive disease on or after the&#xD;
             most recent therapy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score of 0 or 1&#xD;
&#xD;
          -  Women and men must agree to follow specific methods of contraception, if applicable,&#xD;
             while participating in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary central nervous system (CNS) malignancy&#xD;
&#xD;
          -  Other active malignancy requiring concurrent intervention&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>Please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy Sweis, Site 0003</last_name>
      <phone>773-702-1835</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School OF Medicine-Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanner Johanns, Site 0005</last_name>
      <phone>314-362-4140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Luke, Site 0006</last_name>
      <phone>412-623-6121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

